Prevalence, risk factors and awareness of albuminuria on a Canadian First Nation: A community-based screening study

BMC Public Health

Sharon G Bruce⁴  Joanne Roulette²  Natalie D Riediger⁴  T Kue Young³  James Michael Zacharias¹ 

[1] Section of Nephrology, Department of Internal Medicine, Health Sciences Centre, University of Manitoba, Room GE644, 820 Sherbrook St, Winnipeg, Manitoba, R3A 1R9, Canada;Sandy Bay Ojibway First Nation, Sandy Bay Health Centre, Box 110, Marius, Manitoba, R0H 0T0, Canada;Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, Ontario, M5T 3M7, Canada;Department of Community Health Sciences, University of Manitoba, S113-750 Bannatyne Ave, Winnipeg, Manitoba, R3E 0W3, Canada

关键词: Diabetes;    Kidney;    End-stage renal disease;    Albuminuria;    First Nation;    Canada;   

Others  :  1163685
DOI  :  10.1186/1471-2458-12-290

 received in 2011-08-12, accepted in 2012-04-20,  发布年份 2012

【 摘 要 】

Background

Both diabetic and non-diabetic end stage renal disease (ESRD) are more common among Canadian First Nations people than among the general Canadian population. The purpose of this research was to determine the prevalence of and risk factors for albuminuria in a Canadian First Nation population at high risk for ESRD and dialysis.

Methods

Data from a community-based screening study of 483 residents of a Plains Ojibway First Nation in Manitoba was used. Participants provided random urine samples. Proteinuria was defined as any dipstick positive for protein (≥1 g/L) or those with ACR in the macroalbuminuric range (≥30 mg/mmol) on at least one sample. Microalbuminuria was defined as ACR ≥2 mg/mmol for males and ≥2.8 mg/mmol for females. Other measures included fasting glucose, haemoglobin A_1c, triglycerides, cholesterol, blood pressure, height, weight and waist and hip circumferences.

Results

Twenty percent of study participants had albuminuria, (5% proteinuria and 15% microalbuminuria). Of participants with diabetes, 42% (56/132) had albuminuria compared to 26% (7/27) among those with impaired fasting glucose and 10% (30/303) among those with normal glucose tolerance. Only 5.3% of those with albuminuria were aware of any degree of renal disease. In a multivariate logistic regression, independent associations with albuminuria were male gender [p = 0.002], increasing fasting glucose [p <0.0001], years diagnosed with diabetes [p = 0.03], increasing systolic blood pressure [p = 0.009], and increasing body mass index (BMI) [p = 0.04].

Conclusions

The independent association between BMI and albuminuria has not been previously reported among indigenous populations. There is a high prevalence of albuminuria in this Canadian First Nation population; the high proportion of patients with diabetes and undiagnosed kidney disease demonstrates the need for screening, education and intervention to halt the progression and development of albuminuria and ultimately ESRD and CVD.

【 授权许可】

   
2012 Zacharias et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Young TK, Kaufert JM, McKenzie JK, Hawkins A, O’Neil J: Excessive burden of end-stage renal disease among Canadian Indians: a national survey. Am J Public Health 1989, 79:756-758.
• [2]Dyck RF, Tan L: Rates and outcome of diabetic end-stage renal disease among registered native people in Saskatchewan. CMAJ 1994, 150:203-208.
• [3]Dyck RF, Tan L: Non-diabetic end-stage renal disease among Saskatchewan aboriginal people. Clin Invest Med 1998, 21:33-38.
• [4]Stidley CA, Shah VO, Scavini M, Narva AS, Kessler D, Bobelu A, et al.: The Zuni kidney project: a collaborative approach to an epidemic of kidney disease. J Am Soc Nephrol 2003, 14:S139-S143.
• [5]Sosenko JM, Hu D, Welty T, Howard BV, Lee E, Robbins DC: Albuminuria in recent-onset type 2 diabetes: the Strong Heart Study. Diabetes Care 2002, 25:1078-1084.
• [6]Hirata-Dulas CA, Rith-Najarian SJ, McIntyre MC, Ross C, Dahl DC, Keane WF, et al.: Risk factors for nephropathy and cardiovascular disease in diabetic Northern Minnesota American Indians. Clin Nephrol 1996, 46:92-98.
• [7]Nelson RG, Kunzelman CL, Pettitt DJ, Saad MF, Bennett PH, Knowler WC: Albuminuria in type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia 1989, 32:870-876.
• [8]Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, Bennett PH: Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care 1995, 18:182-187.
• [9]Weir MR: Albuminuria predicting outcome in diabetes: incidence of microalbuminuria in Asia-Pacific Rim. Kidney Int 2004, 66:S38-S39. Suppl
• [10]Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
• [11]Mogensen CE: Management of early nephropathy in diabetic patients. Annu Rev Med 1995, 46:79-93.
• [12]Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073-2081.
• [13]Belasco AG, Sesso R: Burden and quality of life for caregivers for hemodialysis patients. Am J Kidney Dis 2002, 39:805-812.
• [14]Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT, et al.: Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. Am J Kidney Dis 1997, 29:584-592.
• [15]Moist LM, Bragg-Gresham JL, Pisoni RL, Saran R, Akiba T, Jacobson SH, et al.: Travel time to dialysis as a predictor of health-related quality of life, adherence and mortality: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008, 51:641-650.
• [16]Zelmer JL: The economic burden of end-stage renal disease in Canada. Kidney Int 2007, 72:1122-1129.
• [17]Tobe SW, Pylypchuk G, Wentworth J, Kiss A, Szalai JP, Perkins N, et al.: Effect of nurse-directed hypertension treatment among First Nations people with existing hypertension and diabetes mellitus: the Diabetes Risk-Evaluation and Microalbuminuria (DREAM 3) randomized controlled trial. CMAJ 2006, 174:1267-1271.
• [18]Kshirsager AV, Joy MS, Hogan HL, Falk RJ, Colindres RE: Effect of Ace inhibitors in Diabetic and Non-Diabetic Chronic Renal Disease: a Systematic Overview of Randomized Placebo-Controlled Trials. Am J Kidney Dis 2000, 35:695-707.
• [19]Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, et al.: Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003, 14:641-647.
• [20]Young TK, Reading J, Elias B, O'Neil JD: Type 2 diabetes mellitus in Canada's first nations: status of an epidemic in progress. CMAJ 2000, 163:561-566.
• [21]Pylypchuk G, Vincent L, Wentworth J, Kiss A, Perkins N, Hartman S, et al.: Diabetes Risk Evaluation and Microalbuminuria (DREAM) studies: ten years of participatory research with a First Nation's home and Community Model for type 2 Diabetes Care in Northern Saskatchewan. Int J of Circumpolar Health 2008, 67:190-202.
• [22]McFarlane P, Culleton B: Canadian Diabetes Associate Clinical Practice Guidelines Expert Committee: Chonic Kidney Disease in Diabetes. Can J Diabetes 2008, 32:S126-S133.
• [23]Bruce SG, Young TK: Prevalence and risk factors for neuropathy in a Canadian First Nation community. Diabetes Care 2008, 31:1837-1841.
• [24]Collins AC, Vincent J, Newall RG, Mitchell KM, Viberti GC: An aid to the early detection and management of diabetic nephropathy: assessment of a new point of care microalbuminuria system in the diabetic clinic. Diabet Med 2001, 18:928-932.
• [25]Parsons M, Newman DJ, Pugia M, Newall RG, Price CP: Performance of a reagent strip device for quantitation of the urine albumin: creatinine ratio in a point of care setting. Clin Nephrol 1999, 51:220-227.
• [26]Canadian Diabetes Association: Clinical practice guidelines for the prevention and management of Diabetes in Canada. Can J Diabetes 2008, 32(Suppl 1):S126-S133.
• [27]American Diabetes Association: Executive summary: standards of medical care in diabetes −2011. Diabetes Care 2011, 34:S4-S10.
• [28]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
• [29]The Canadian Physical Activity, Fitness and Lifestyle appraisal. CSEP; 1996.
• [30]Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, et al.: Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005, 16:180-188.
• [31]Brassard P, Robinson E, Dumont C: Descriptive epidemiology of non-insulin-dependent diabetes mellitus in the James Bay Cree population of Quebec, Canada. Arctic Med Res 1993, 52:47-54.
• [32]Morrison N, Dooley J: The Sioux Lookout Diabetes Program: diabetes prevention and management in northwestern Ontario. Int J Circumpolar Health 1998, 57:364-369.
• [33]Young TK, Szathmary EJ, Evers S, Wheatley B: Geographical distribution of diabetes among the native population of Canada: a national survey. Soc Sci Med 1990, 31:129-139.
• [34]Rigatto C, Bernstein K: Abstract: trends in incidence and prevalence of diabetic (D) and non-diabetic (ND) end-stage renal disease (ESRD) in First Nations (FN) and non-First Nations adults in Manitoba: 1997 to 2003. J Am Soc Nephrol 2005, 16:295A.
• [35]Shah VO, Scavini M, Stidley CA, Tentori F, Welty TK, MacCluer JW, et al.: Epidemic of diabetic and nondiabetic renal disease among the Zuni Indians: the Zuni Kidney Project. J Am Soc Nephrol 2003, 14:1320-1329.
• [36]Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, et al.: Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002, 39:445-459.
• [37]Robbins DC, Knowler WC, Lee ET, Yeh J, Go OT, Welty T, et al.: Regional differences in albuminuria among American Indians: an epidemic of renal disease. Kidney Int 1996, 49:557-563.
• [38]Houlihan CA, Tsalamandris C, Akdeniz A, Jerums G: Albumin to creatinine ratio: a screening test with limitations. Am J Kidney Dis 2002, 39:1183-1189.
• [39]Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, et al.: Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995, 18:572-581.
• [40]Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996, 7:930-937.
• [41]Romundstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H: Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trondelag Health Study (HUNT), Norway. Circulation 2003, 108:2783-2789.
• [42]Afghahi H, Cederholm J, Eliasson B, Zethelius B, Gudbjrnsdottir S, Hadimeri H, Svensson MK: Risk factors for the development of albuminuria and renal impairment in type 2 diabetes. The Swedish Nation Diabetes Register (NDR). Nephrol Dial Transplant 2011, 26(4):1236-1243.
• [43]Katzmarzyk PT, Malina RM: Body size and physique among Canadians of First Nation and European ancestry. Am J Phys Anthropol 1999, 108:161-172.
• [44]Katzmarzyk PT, Malina RM: Obesity and relative subcutaneous fat distribution among Canadians of First Nation and European ancestry. Int J Obes Relat Metab Disord 1998, 22:1127-1131.
• [45]Young TK, Sevenhuysen GP, Ling N, Moffatt ME: Determinants of plasma glucose level and diabetic status in a northern Canadian Indian population. CMAJ 1990, 142:821-830.
• [46]Mykkanen L, Haffner SM, Kuusisto J, Pyorala K, Laakso M: Microalbuminuria precedes the development of NIDDM. Diabetes 1994, 43:552-557.